AI Tokens
Stock Analysis on Net

CVS Health Corp. (NYSE:CVS)

This company has been moved to the archive! The financial data has not been updated since May 1, 2025.

Analysis of Income Taxes

Microsoft Excel

Income Tax Expense (Benefit)

CVS Health Corp., income tax expense (benefit), continuing operations

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Federal 1,658 2,819 2,803 2,285 2,615
State 476 662 735 665 518
Current 2,134 3,481 3,538 2,950 3,133
Federal (453) (537) (1,569) (306) (450)
State (119) (139) (506) (122) (114)
Deferred (572) (676) (2,075) (428) (564)
Income tax provision 1,562 2,805 1,463 2,522 2,569

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


The income tax profile from 2020 through 2024 is characterized by volatility in the total income tax provision, driven primarily by fluctuations in deferred tax benefits and a notable reduction in current tax liabilities in the final year of the analyzed period.

Current Tax Expense Trends
Current tax obligations remained relatively stable between 2020 and 2023, oscillating between 2,950 million and 3,538 million. A significant contraction is observed in 2024, where the expense declined to 2,134 million, marking the lowest current tax liability within the five-year window.
Deferred Tax Impact
Deferred taxes consistently provided a benefit throughout the period, as evidenced by the negative values recorded annually. A substantial spike in this benefit occurred in 2022, reaching 2,075 million, which deviates significantly from the benefit range observed in other years, which typically fluctuated between 428 million and 676 million.
Total Income Tax Provision Analysis
The total income tax provision exhibited a non-linear trajectory, heavily influenced by the interplay between current expenses and deferred benefits. The provision reached a minimum of 1,463 million in 2022, a result of the exceptional deferred tax benefit recorded that year. Despite a recovery to 2,805 million in 2023, the provision fell again to 1,562 million in 2024, primarily reflecting the diminished current tax expense.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Effective Income Tax Rate (EITR)

CVS Health Corp., effective income tax rate (EITR) reconciliation

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Statutory income tax rate 21.00% 21.00% 21.00% 21.00% 21.00%
State income taxes, net of federal tax benefit 4.60% 3.70% 3.20% 4.10% 3.20%
Health insurer fee 0.00% 0.00% 0.00% 0.00% 2.20%
Legal charges 0.50% 0.00% 3.50% 0.00% 0.00%
Basis difference upon disposition of subsidiary 0.00% 0.00% 1.70% 0.00% -1.20%
Prior year refunds and unrecognized tax benefits 0.00% 0.00% -2.70% -1.20% 0.00%
Tax credits -1.20% -0.30% -0.60% 0.00% 0.00%
Other 0.50% 0.70% -0.10% 0.30% 1.10%
Effective income tax rate 25.40% 25.10% 26.00% 24.20% 26.30%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


The effective income tax rate (EITR) remained consistently above the statutory rate of 21.00% throughout the period from 2020 to 2024. The EITR exhibited moderate fluctuation, peaking at 26.30% in 2020 and reaching a minimum of 24.20% in 2021, before stabilizing between 25.10% and 25.40% in the most recent two years.

Factors Increasing the Effective Tax Rate
State income taxes, net of federal tax benefits, served as a constant upward driver, ranging from 3.20% to 4.60%, with the highest impact recorded in 2024.
Non-recurring expenses introduced periodic volatility; legal charges added 3.50% to the rate in 2022 and 0.50% in 2024, while a health insurer fee contributed 2.20% in 2020.
The basis difference upon disposition of subsidiaries had a variable effect, providing a tax benefit of -1.20% in 2020 but increasing the rate by 1.70% in 2022.
Factors Decreasing the Effective Tax Rate
Tax credits became a steady downward influence starting in 2022, with the reduction increasing incrementally from -0.60% in 2022 to -1.20% in 2024.
Prior year refunds and unrecognized tax benefits provided significant temporary reductions in 2021 and 2022, with the most pronounced effect being a -2.70% reduction in 2022.

The analysis indicates that while the statutory rate remained static, the EITR was primarily pushed upward by state-level taxes and occasional legal costs. These increases were partially mitigated by a growing reliance on tax credits and periodic gains from prior year tax adjustments.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Components of Deferred Tax Assets and Liabilities

CVS Health Corp., components of deferred tax assets and liabilities

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Lease and rents 4,763 5,059 5,242 5,563 5,742
Legal charges 1,109 1,205 1,260 19 —
Inventory 68 94 103 99 80
Employee benefits 168 168 153 193 238
Bad debts and other allowances 593 606 480 489 395
Net operating loss and capital loss carryforwards 272 409 266 416 568
Deferred income 47 62 66 78 43
Insurance reserves 381 356 455 501 489
Investments 21 56 293 — —
Payroll tax deferral — — — 87 173
Other 486 372 335 377 500
Deferred income tax assets, before valuation allowance 7,908 8,387 8,653 7,822 8,228
Valuation allowance (301) (385) (532) (325) (454)
Deferred income tax assets 7,607 8,002 8,121 7,497 7,774
Retirement benefits (172) (112) (92) (105) (29)
Investments — — — (334) (421)
Lease and rents (4,125) (4,469) (4,639) (4,947) (5,368)
Depreciation and amortization (7,116) (7,732) (7,139) (8,381) (8,750)
Deferred income tax liabilities (11,413) (12,313) (11,870) (13,767) (14,568)
Net deferred income tax assets (liabilities) (3,806) (4,311) (3,749) (6,270) (6,794)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


The net deferred income tax position has transitioned from a liability of 6,794 million USD in 2020 to a reduced liability of 3,806 million USD by 2024. This overall reduction in net deferred tax liabilities is primarily driven by a contraction in the gross deferred tax liability balance, which declined from 14,568 million USD to 11,413 million USD over the five-year period.

Analysis of Deferred Tax Assets
Gross deferred tax assets before valuation allowances peaked in 2022 at 8,653 million USD before declining to 7,908 million USD by 2024. A significant shift is observed in legal charges, which rose from negligible amounts in 2020 to 1,109 million USD in 2024, indicating a substantial increase in deductible temporary differences related to legal expenditures. Conversely, assets related to leases and rents have steadily decreased from 5,742 million USD in 2020 to 4,763 million USD in 2024. Bad debts and other allowances have shown a general upward trend, increasing from 395 million USD to 593 million USD.
Analysis of Deferred Tax Liabilities
Deferred tax liabilities have decreased consistently from 14,568 million USD in 2020 to 11,413 million USD in 2024. The primary driver of this reduction is depreciation and amortization, which fell from 8,750 million USD to 7,116 million USD. Similarly, liabilities associated with leases and rents declined from 5,368 million USD to 4,125 million USD. In contrast, retirement benefits have seen an increase in liability, growing from 29 million USD in 2020 to 172 million USD in 2024.
Valuation Allowance and Net Asset Positioning
The valuation allowance has fluctuated, reaching its highest absolute value of 532 million USD in 2022 before decreasing to 301 million USD in 2024. This suggests a dynamic assessment of the realizability of deferred tax assets. The resulting net deferred tax assets remained relatively stable, moving from 7,774 million USD in 2020 to 7,607 million USD in 2024, indicating that the growth in certain asset categories, such as legal charges, has largely offset the decline in lease-related assets.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Deferred Tax Assets and Liabilities, Classification

CVS Health Corp., deferred tax assets and liabilities, classification

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Deferred income tax assets — — 131 — —
Deferred income tax liabilities 3,806 4,311 3,880 6,270 6,794

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


The company maintains a consistent net deferred tax liability position throughout the analyzed period. A general downward trend in these liabilities is observed, despite a temporary increase in 2023, indicating a significant reduction in the future tax obligations recognized on the balance sheet over the five-year span.

Deferred Income Tax Liabilities
A substantial reduction in deferred tax liabilities occurred between 2020 and 2024. Starting at 6,794 million US dollars in 2020, the liabilities declined to 6,270 million US dollars in 2021 and further dropped to 3,880 million US dollars by the end of 2022. While a moderate increase to 4,311 million US dollars was recorded in 2023, the balance returned to a downward trajectory, ending at 3,806 million US dollars in 2024. This represents an overall decrease of approximately 44% from the initial 2020 level.
Deferred Income Tax Assets
Deferred tax assets are largely absent from the records for the majority of the period. A nominal amount of 131 million US dollars was reported exclusively for the period ending December 31, 2022. The lack of consistent reporting for these assets suggests that they do not play a material role in the company's overall tax strategy or balance sheet structure compared to the liabilities.
Net Tax Position Analysis
The disproportionate relationship between deferred tax assets and liabilities confirms a sustained net liability position. The volatility observed in the liabilities between 2022 and 2024 suggests fluctuations in temporary differences between accounting and tax treatments, though the long-term trend points toward a reduction in the total deferred tax burden.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjustments to Financial Statements: Removal of Deferred Taxes

CVS Health Corp., Financial Data: Reported vs. Adjusted

CVS Health Corp., adjustments to financial statements

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Adjustment to Total Assets
Total assets (as reported) 253,215 249,728 228,275 232,999 230,715
Less: Noncurrent deferred tax assets, net — — 131 — —
Total assets (adjusted) 253,215 249,728 228,144 232,999 230,715
Adjustment to Total Liabilities
Total liabilities (as reported) 177,485 173,092 156,960 157,618 161,014
Less: Noncurrent deferred tax liabilities, net 3,806 4,311 3,880 6,270 6,794
Total liabilities (adjusted) 173,679 168,781 153,080 151,348 154,220
Adjustment to Total CVS Health Shareholders’ Equity
Total CVS Health shareholders’ equity (as reported) 75,560 76,461 71,015 75,075 69,389
Less: Net deferred tax assets (liabilities) (3,806) (4,311) (3,749) (6,270) (6,794)
Total CVS Health shareholders’ equity (adjusted) 79,366 80,772 74,764 81,345 76,183
Adjustment to Net Income Attributable To CVS Health
Net income attributable to CVS Health (as reported) 4,614 8,344 4,149 7,910 7,179
Add: Deferred income tax expense (benefit) (572) (676) (2,075) (428) (564)
Net income attributable to CVS Health (adjusted) 4,042 7,668 2,074 7,482 6,615

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


An examination of the financial position from 2020 to 2024 reveals a consistent divergence between reported and adjusted values, primarily stemming from the removal of deferred tax elements. Total assets exhibit a general upward trajectory, increasing from 230,715 million US dollars in 2020 to 253,215 million US dollars by the end of 2024.

Balance Sheet Adjustments
A systematic reduction in liabilities is observed when transitioning from reported to adjusted figures. In 2020, adjusted total liabilities were 154,220 million US dollars compared to reported liabilities of 161,014 million US dollars. This reduction corresponds to a proportional increase in adjusted shareholders' equity, which stood at 76,183 million US dollars in 2020 against a reported 69,389 million US dollars. This inverse relationship indicates that the removal of deferred tax liabilities serves to augment the adjusted equity position.
Net Income Variability
The adjustment process results in an adjusted net income that is consistently lower than the reported net income. The most significant variance occurred in 2022, where reported net income of 4,149 million US dollars was adjusted downward to 2,074 million US dollars. While reported net income peaked in 2023 at 8,344 million US dollars, the adjusted figure remained lower at 7,668 million US dollars, highlighting a persistent downward adjustment to profitability after the removal of deferred tax effects.
Asset and Equity Trends
Reported total assets grew by approximately 9.7% over the five-year period. Shareholders' equity showed more volatility, with reported equity fluctuating between 69,389 million US dollars in 2020 and 75,560 million US dollars in 2024. However, adjusted equity remained consistently higher than reported equity throughout the entire duration, peaking in 2023 at 80,772 million US dollars.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjusted Financial Ratios: Removal of Deferred Taxes (Summary)

CVS Health Corp., Financial Ratios: Reported vs. Adjusted

CVS Health Corp., adjusted financial ratios

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net Profit Margin
Reported net profit margin 1.24% 2.34% 1.29% 2.72% 2.68%
Adjusted net profit margin 1.09% 2.15% 0.64% 2.57% 2.47%
Total Asset Turnover
Reported total asset turnover 1.46 1.43 1.41 1.25 1.16
Adjusted total asset turnover 1.46 1.43 1.41 1.25 1.16
Financial Leverage
Reported financial leverage 3.35 3.27 3.21 3.10 3.32
Adjusted financial leverage 3.19 3.09 3.05 2.86 3.03
Return on Equity (ROE)
Reported ROE 6.11% 10.91% 5.84% 10.54% 10.35%
Adjusted ROE 5.09% 9.49% 2.77% 9.20% 8.68%
Return on Assets (ROA)
Reported ROA 1.82% 3.34% 1.82% 3.39% 3.11%
Adjusted ROA 1.60% 3.07% 0.91% 3.21% 2.87%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


An analysis of the financial ratios from 2020 to 2024 reveals a consistent divergence between reported and adjusted metrics resulting from the removal of deferred taxes. Across the five-year period, adjusted figures for profitability and leverage are systematically lower than reported figures, indicating that deferred tax components provide a positive contribution to reported net income and impact the equity base.

Profitability Margins and Returns
Reported net profit margins exhibited volatility, peaking at 2.72% in 2021 before declining to 1.24% by 2024. The adjusted net profit margin followed an identical trajectory but remained consistently lower, reaching a low of 0.64% in 2022 and 1.09% in 2024. This pattern is mirrored in the Return on Assets (ROA) and Return on Equity (ROE). The adjusted ROE shows a significant reduction compared to reported ROE, particularly in 2022 where the adjusted value dropped to 2.77% against a reported 5.84%. The most pronounced volatility in returns occurred in 2022 and 2024, where both reported and adjusted metrics experienced sharp contractions.
Asset Utilization
Total asset turnover demonstrates a steady and linear upward trend, increasing from 1.16 in 2020 to 1.46 in 2024. Notably, there is no variance between the reported and adjusted total asset turnover ratios. This indicates that the removal of deferred taxes has no impact on the measurement of operational efficiency regarding asset utilization.
Financial Leverage
Financial leverage ratios remained relatively stable but showed a gradual increase toward the end of the period. Reported leverage rose from 3.32 in 2020 to 3.35 in 2024, while adjusted leverage moved from 3.03 to 3.19. The consistent gap between the two metrics suggests that deferred tax adjustments reduce the reported leverage, implying that the tax-related adjustments influence the valuation of equity more than the valuation of total assets.

Overall, the data indicates that while operational asset efficiency has improved consistently, the bottom-line profitability remains volatile. The systemic gap between reported and adjusted ratios underscores the material influence of deferred taxes on the company's reported financial performance and capital structure.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjusted Net Profit Margin

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to CVS Health 4,614 8,344 4,149 7,910 7,179
Revenues from customers 370,656 356,623 321,629 290,912 267,908
Profitability Ratio
Net profit margin1 1.24% 2.34% 1.29% 2.72% 2.68%
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted net income attributable to CVS Health 4,042 7,668 2,074 7,482 6,615
Revenues from customers 370,656 356,623 321,629 290,912 267,908
Profitability Ratio
Adjusted net profit margin2 1.09% 2.15% 0.64% 2.57% 2.47%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

1 Net profit margin = 100 × Net income attributable to CVS Health ÷ Revenues from customers
= 100 × 4,614 ÷ 370,656 = 1.24%

2 Adjusted net profit margin = 100 × Adjusted net income attributable to CVS Health ÷ Revenues from customers
= 100 × 4,042 ÷ 370,656 = 1.09%


Analysis of profitability from 2020 to 2024 reveals a pattern of significant volatility in both reported and adjusted earnings. Performance peaks occurred in 2021 and 2023, with pronounced contractions observed in 2022 and 2024.

Reported Net Income and Profit Margin
Reported net income grew from US$ 7,179 million in 2020 to US$ 7,910 million in 2021, followed by a sharp contraction to US$ 4,149 million in 2022. A substantial recovery was recorded in 2023, reaching a five-year peak of US$ 8,344 million, before declining to US$ 4,614 million in 2024. The reported net profit margin mirrored this volatility, peaking at 2.72% in 2021 and reaching its lowest point of 1.24% in 2024.
Adjusted Net Income and Profit Margin
Adjusted net income exhibited more extreme fluctuations than reported figures, particularly in 2022, when it fell to US$ 2,074 million from US$ 7,482 million in 2021. This resulted in an adjusted net profit margin of 0.64%, the lowest margin across all metrics in the period. Although a recovery to US$ 7,668 million and a 2.15% margin was achieved in 2023, the adjusted net income fell to US$ 4,042 million by 2024, with a corresponding margin of 1.09%.
Comparative Variance Analysis
A persistent variance is observed between reported and adjusted metrics, indicating the influence of non-recurring items. The discrepancy was most acute in 2022, where reported net income was significantly higher than adjusted net income, suggesting that one-time gains or credits bolstered the reported results while the adjusted operational performance was considerably weaker. In 2024, the gap narrowed, though the adjusted net profit margin remained lower than the reported margin.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjusted Total Asset Turnover

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Revenues from customers 370,656 356,623 321,629 290,912 267,908
Total assets 253,215 249,728 228,275 232,999 230,715
Activity Ratio
Total asset turnover1 1.46 1.43 1.41 1.25 1.16
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Revenues from customers 370,656 356,623 321,629 290,912 267,908
Adjusted total assets 253,215 249,728 228,144 232,999 230,715
Activity Ratio
Adjusted total asset turnover2 1.46 1.43 1.41 1.25 1.16

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

1 Total asset turnover = Revenues from customers ÷ Total assets
= 370,656 ÷ 253,215 = 1.46

2 Adjusted total asset turnover = Revenues from customers ÷ Adjusted total assets
= 370,656 ÷ 253,215 = 1.46


An analysis of asset utilization metrics from 2020 through 2024 reveals a consistent upward trajectory in operational efficiency, characterized by a steady increase in the asset turnover ratio alongside a general expansion of the total asset base.

Total Asset Trends
Total assets exhibited relative stability between 2020 and 2022, with a slight peak in 2021 at US$ 232,999 million followed by a minor contraction to US$ 228,275 million in 2022. A significant expansion phase began in 2023, with reported total assets increasing to US$ 249,728 million and further rising to US$ 253,215 million by the end of 2024. The difference between reported and adjusted total assets is negligible across the period, with only a marginal variance noted in 2022.
Adjusted Total Asset Turnover Analysis
The adjusted total asset turnover ratio demonstrates a continuous year-over-year improvement, ascending from 1.16 in 2020 to 1.46 in 2024. The most pronounced growth in efficiency occurred between 2021 and 2022, where the ratio climbed from 1.25 to 1.41. This trend indicates a progressive enhancement in the company's ability to generate revenue relative to its invested asset base.

The correlation between the expanding asset base in 2023 and 2024 and the continuing rise in the turnover ratio suggests that recent capital allocations have been effectively deployed to drive revenue growth. The identical values between reported and adjusted turnover ratios indicate that no significant adjustments were required to normalize the efficiency metrics during this period.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjusted Financial Leverage

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Total assets 253,215 249,728 228,275 232,999 230,715
Total CVS Health shareholders’ equity 75,560 76,461 71,015 75,075 69,389
Solvency Ratio
Financial leverage1 3.35 3.27 3.21 3.10 3.32
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted total assets 253,215 249,728 228,144 232,999 230,715
Adjusted total CVS Health shareholders’ equity 79,366 80,772 74,764 81,345 76,183
Solvency Ratio
Adjusted financial leverage2 3.19 3.09 3.05 2.86 3.03

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

1 Financial leverage = Total assets ÷ Total CVS Health shareholders’ equity
= 253,215 ÷ 75,560 = 3.35

2 Adjusted financial leverage = Adjusted total assets ÷ Adjusted total CVS Health shareholders’ equity
= 253,215 ÷ 79,366 = 3.19


An examination of the financial position from 2020 through 2024 reveals a consistent discrepancy between reported and adjusted financial metrics, primarily driven by differences in the valuation of shareholders' equity. Total assets remained relatively stable between 2020 and 2022 before experiencing a notable increase in 2023, rising from 228,275 million USD to 249,728 million USD, and continuing a slight upward trajectory into 2024.

Shareholders' Equity Trends
Adjusted total shareholders' equity consistently exceeds reported equity across the entire five-year period. In 2020, the adjusted equity of 76,183 million USD was approximately 9.8% higher than the reported 69,389 million USD. This gap persisted through 2024, where adjusted equity stood at 79,366 million USD compared to a reported 75,560 million USD. The adjustment suggests a systematic revaluation of equity components that strengthens the balance sheet position.
Financial Leverage Analysis
Reported financial leverage exhibited a fluctuating trend, declining from 3.32 in 2020 to a low of 3.10 in 2021, before trending upward to reach a period peak of 3.35 by December 31, 2024. The adjusted financial leverage mirrored this trajectory but remained consistently lower than the reported figures. Adjusted leverage decreased from 3.03 in 2020 to 2.86 in 2021, subsequently rising to 3.19 in 2024.
Comparative Leverage Insights
The use of adjusted metrics results in a lower calculated leverage ratio in every observed year. This indicates that the adjustments to shareholders' equity effectively reduce the perceived risk associated with the company's asset-to-equity ratio. While both reported and adjusted leverage increased between 2021 and 2024, the adjusted ratio provides a more conservative assessment of the company's financial gearing.

The overall trend indicates an expansion of the asset base starting in 2023, accompanied by a gradual increase in financial leverage over the last three years. However, the persistent gap between reported and adjusted leverage highlights the significant impact of specific equity adjustments on the interpretation of the company's solvency and capital structure.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjusted Return on Equity (ROE)

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to CVS Health 4,614 8,344 4,149 7,910 7,179
Total CVS Health shareholders’ equity 75,560 76,461 71,015 75,075 69,389
Profitability Ratio
ROE1 6.11% 10.91% 5.84% 10.54% 10.35%
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted net income attributable to CVS Health 4,042 7,668 2,074 7,482 6,615
Adjusted total CVS Health shareholders’ equity 79,366 80,772 74,764 81,345 76,183
Profitability Ratio
Adjusted ROE2 5.09% 9.49% 2.77% 9.20% 8.68%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

1 ROE = 100 × Net income attributable to CVS Health ÷ Total CVS Health shareholders’ equity
= 100 × 4,614 ÷ 75,560 = 6.11%

2 Adjusted ROE = 100 × Adjusted net income attributable to CVS Health ÷ Adjusted total CVS Health shareholders’ equity
= 100 × 4,042 ÷ 79,366 = 5.09%


The financial performance of CVS Health from 2020 to 2024 is characterized by significant volatility in profitability metrics contrasted with relatively stable equity levels. While the company experienced peaks in net income and return on equity (ROE) in 2021 and 2023, there were substantial declines in 2022 and 2024, suggesting periodic instability in earnings.

Net Income Performance
Reported net income exhibits a fluctuating trend, peaking at US$ 8,344 million in 2023 before falling to US$ 4,614 million in 2024. Adjusted net income follows a similar trajectory but demonstrates more extreme variance; it plummeted to a low of US$ 2,074 million in 2022, representing a significant deviation from reported figures in that year.
Shareholders' Equity Trends
Both reported and adjusted shareholders' equity remained relatively consistent throughout the period. Reported equity grew from US$ 69,389 million in 2020 to US$ 75,560 million in 2024. Adjusted equity peaked in 2021 at US$ 81,345 million and remained above US$ 74,000 million for the duration of the five-year span, indicating a stable capital base.
Return on Equity (ROE) Analysis
The volatility in net income is directly reflected in the ROE metrics. Reported ROE reached its highest point of 10.91% in 2023 but dropped to 6.11% by 2024. Adjusted ROE consistently tracked lower than reported ROE, experiencing a severe contraction to 2.77% in 2022. The gap between reported and adjusted ROE suggests that non-recurring items or specific adjustments have a meaningful impact on the company's perceived equity efficiency.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Adjusted Return on Assets (ROA)

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to CVS Health 4,614 8,344 4,149 7,910 7,179
Total assets 253,215 249,728 228,275 232,999 230,715
Profitability Ratio
ROA1 1.82% 3.34% 1.82% 3.39% 3.11%
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted net income attributable to CVS Health 4,042 7,668 2,074 7,482 6,615
Adjusted total assets 253,215 249,728 228,144 232,999 230,715
Profitability Ratio
Adjusted ROA2 1.60% 3.07% 0.91% 3.21% 2.87%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

1 ROA = 100 × Net income attributable to CVS Health ÷ Total assets
= 100 × 4,614 ÷ 253,215 = 1.82%

2 Adjusted ROA = 100 × Adjusted net income attributable to CVS Health ÷ Adjusted total assets
= 100 × 4,042 ÷ 253,215 = 1.60%


An analysis of financial performance from 2020 to 2024 reveals significant volatility in profitability metrics, which is directly reflected in the fluctuations of the adjusted return on assets (ROA). While the asset base has remained relatively stable with a gradual upward trend, the adjusted net income has experienced sharp contractions and recoveries, leading to an inconsistent asset utilization efficiency.

Net Income Volatility
Adjusted net income exhibits substantial variance over the five-year period. A notable decline occurred in 2022, where adjusted net income dropped to 2,074 million US$, a significant decrease from the 7,482 million US$ recorded in 2021. Although a recovery was observed in 2023 with income rising to 7,668 million US$, a subsequent decline to 4,042 million US$ occurred by the end of 2024. Throughout this period, adjusted net income consistently remained below reported net income, suggesting that adjustments for non-recurring items or specific accounting treatments typically reduced the net earnings figure.
Asset Base Stability
Total assets, both reported and adjusted, demonstrate a steady growth pattern. Assets increased from 230,715 million US$ in 2020 to 253,215 million US$ in 2024. The consistency between reported and adjusted total assets indicates that the adjustments applied to the balance sheet were minimal, meaning the fluctuations in ROA are primarily driven by changes in net income rather than shifts in the asset base.
Adjusted ROA Performance
The adjusted ROA reflects the instability of the adjusted net income relative to the growing asset base. The ratio peaked in 2021 at 3.21% before plummeting to a period low of 0.91% in 2022. A strong rebound to 3.07% was achieved in 2023, followed by a decline to 1.60% in 2024. The consistent gap between reported ROA and adjusted ROA highlights that the underlying adjusted operational performance is lower than the reported figures, particularly during the downturns of 2022 and 2024.

The overarching trend indicates a cyclical pattern of profitability. The divergence between the steadily increasing total assets and the volatile adjusted net income suggests that the company has struggled to maintain a consistent rate of return on its expanded asset base, with 2022 and 2024 serving as significant periods of diminished asset efficiency.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?